BioCentury | Dec 31, 2016

Delivering takeouts

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking...
BioCentury | Jan 11, 2016

Sowing season

Stephen Hansen, Associate Editor BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This...
BioCentury | Jan 13, 2014

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BioCentury | Jan 7, 2013

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer A strong crop of early PDUFA dates and a sense that FDA is more navigable have given money managers in the U.S. and Europe a positive outlook for 2013, which they...
Items per page:
1 - 4 of 4